Tyrosine kinase alterations in colorectal cancer with emphasis on the distinct clinicopathological characteristics
- 28 July 2023
- journal article
- research article
- Published by Wiley in Histopathology
- Vol. 83 (5) , 733-742
Abstract
Aims: Tyrosine kinase (TK) alterations, such as anaplastic lymphoma kinase (ALK) fusion, neurotrophic tyrosine receptor kinase (NTRK) fusion, c‐ros oncogene 1 (ROS1) fusion and mesenchymal–epithelial transition factor (MET) exon 14 skipping, have been reported in colorectal cancers (CRC). We have previously reported CRCs with NTRK fusion among our cohort. However, their clinicopathological features have not been fully elucidated.Methods and results: Tissue microarray (TMA)‐based immunohistochemistry (IHC) was performed on 951 CRC lesions from 944 patients. IHC was evaluated as positive or negative for ALK and ROS1 and 0 to 3+ for c‐MET. For ALK and ROS1 IHC‐positive cases, RNA‐based imbalanced gene expression assays, Archer FusionPlex assays and reverse transcription–polymerase chain reaction (RT‐PCR) followed by Sanger sequencing were performed. For c‐MET IHC 3+ cases, RT‐PCR followed by Sanger sequencing were performed. ALK IHC was positive in three cases (0.2%) and all showed imbalanced ALK gene expression. The following ALK fusions were confirmed: EML4 (exon 21)::ALK (exon 20), EML4 (exon 6)::ALK (exon 19) and HMBOX1 (exon 6)::ALK (exon 20). Two showed microsatellite instability‐high/mismatch repair (MMR)‐deficient, and all were located in the right colon. ROS1 IHC was positive in one case; however, imbalanced expression and ROS1 fusion was negative. Forty‐two cases (4.4%) showed c‐MET IHC3+. MET exon 14 skipping was confirmed in nine cases. All cases were microsatellite stable/MMR‐proficient, and eight were located in the left colon and rectum.Conclusions: CRCs with these TK alterations had distinct clinicopathological features. Together with our previous study, 15 cases (1.6%) harboured targetable TK alterations (three NTRK fusion, three ALK fusion, nine MET exon 14 skipping).Keywords
Funding Information
- Japan Society for the Promotion of Science (22K15430, 20K07415)
This publication has 31 references indexed in Scilit:
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET InhibitorsCancer Discovery, 2015
- ROS1 Immunohistochemistry Among Major Genotypes of Non–Small-Cell Lung CancerClinical Lung Cancer, 2015
- ALK and ROS1 Overexpression is Very Rare in Colorectal AdenocarcinomaApplied Immunohistochemistry & Molecular Morphology, 2015
- Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancersLaboratory Investigation, 2014
- ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular DriversMolecular Cancer Research, 2014
- Tyrosine kinase gene rearrangements in epithelial malignanciesNature Reviews Cancer, 2013
- Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase FusionsClinical Cancer Research, 2012
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsiesNature Medicine, 2012
- Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never SmokersPLOS ONE, 2011
- c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastasesCancer Letters, 2008